(ZEG) AstraZeneca - Ratings and Ratios

AstraZeneca PLC (XETRA:ZEG) is a global biopharmaceutical company specializing in the discovery, development, and commercialization of innovative prescription medicines. The company operates across multiple therapeutic areas, including oncology, cardiovascular, renal and metabolism, respiratory and immunology, vaccines and immune therapies, and rare diseases. Its product portfolio includes a wide range of treatments, such as Imfinzi for oncology, Farxiga for type 2 diabetes, and Symbicort for respiratory conditions. AstraZeneca also collaborates with academic institutions and industry partners to advance its pipeline, focusing on precision medicine and personalized healthcare solutions.

Headquartered in Cambridge, UK, AstraZeneca was incorporated in 1992 and was formerly known as Zeneca Group PLC until its merger with Astra AB in 1999. The company has a strong presence in over 100 countries, with a network of distributors and local offices. Its commitment to research and development has positioned it as a leader in addressing unmet medical needs, particularly in areas like immuno-oncology and cardiovascular diseases.

From a technical perspective, AstraZenecas stock (ZEG) on the XETRA exchange is currently trading at 118.75, below its 20-day and 50-day simple moving averages (127.48 and 136.03, respectively). The 200-day SMA stands at 135.83, indicating a potential downtrend in the medium term. The average true range (ATR) of 3.48 reflects moderate volatility. The stocks volume over the past 20 days averages 24,100, suggesting consistent trading activity.

Fundamentally, AstraZeneca has a market capitalization of 184.08 billion EUR, with a price-to-earnings (P/E) ratio of 29.76 and a forward P/E of 15.34, signaling expectations of future earnings growth. The price-to-book (P/B) ratio of 6.18 indicates a premium valuation relative to its book value. The companys return on equity (RoE) of 17.25% highlights its ability to generate profits from shareholders equity. The price-to-sales (P/S) ratio of 3.40 reflects its revenue generation capabilities.

3-Month Forecast: Based on the technical and fundamental data, AstraZenecas stock is likely to face resistance at its 20-day and 50-day SMAs (127.48 and 136.03). If the price fails to breach these levels, it may consolidate or trend downward, with potential support near its 200-day SMA (135.83). The forward P/E of 15.34 suggests investor confidence in future earnings, but the current P/E of 29.76 may indicate short-term valuation pressures. The companys strong RoE and established product portfolio provide a stable foundation, but near-term price movements will likely be influenced by broader market sentiment and macroeconomic factors.